Loading stock data…
ANIP
$80.39+0.94 (+1.18%)
Market ClosedLast close May 1
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANI Pharmaceuticals, Inc. in the Healthcare sector is trading at $80.39. The stock is currently 19% below its 52-week high of $99.50, remaining 2.8% below its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why ANIP maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$80.39
Potential Downside
13.4%
Whystock Fair Value$69.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$110.63+37.6%
Range$90.00 – $124.00
Fundamentals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.49%
Volume
Today's trading volume
266,347
Recent News
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ANI Pharmaceuticals (ANIP) Announces Launch of Pimozide Tablets 1 mg and 2 mg
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is one of the best drug stocks to buy according to analysts. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced on April 20 the launch of Pimozide Tablets 1 mg and 2 mg, with the Pimozide Tablets being the generic version of the reference listed drug (RLD) Orap®. The company reported that the US […]
Zacks.com featured highlights include Mirion Technologies, Intuit and ANI Pharmaceuticals
Mirion Technologies, Intuit and ANI Pharmaceuticals stand out with accelerating earnings growth, signaling potential upside before broader market recognition.
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.